Most people with paroxysmal nocturnal hemoglobinuria (PNH) benefited from Soliris (eculizumab) therapy when they adhered to strict treatment guidelines, a real-world Dutch study showed. Because most had an incomplete response, new therapies are needed to improve real-world outcomes, however, the study’s researchers suggested, and emphasized that their data could…
News
Recent Posts
- New study backs approved therapy as a safe, effective treatment for PNH
- Rebuilding self-esteem after a PNH diagnosis
- Soliris helps curb blood clot risk in PNH, but monitoring still needed
- Am I still sick, or have I just forgotten what healthy feels like?
- Switching to Fabhalta boosts hemoglobin, eases fatigue in PNH